Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

Lignende værker

• Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
  af: Telli, Melinda L., et al.
  Udgivet: (2015)
• Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancers
  af: Telli, Melinda L., et al.
  Udgivet: (2016)
• The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
  af: Olga Caramelo, et al.
  Udgivet: (2019-03-01)
• The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
  af: Caramelo, Olga, et al.
  Udgivet: (2019)
• Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
  af: Doherty, Mary R., et al.
  Udgivet: (2017)